Yoann Pradat

Yoann Pradat

CentraleSupélec (comUE Université Paris Saclay) - Gif-sur-Yvette / France
Others
AD Scientific Index ID: 5413699
Central School of Paris
person_outline Yoann Pradat's MOST POPULAR ARTICLES
1-) Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trialF Mosele, E Deluche, A Lusque, L Le Bescond, T Filleron, Y Pradat, ...Nature Medicine 29 (8), 2110-2120, 2023972023
2-) Unified classification and risk-stratification in Acute Myeloid LeukemiaY Tazi, JE Arango-Ossa, Y Zhou, E Bernard, I Thomas, A Gilkes, ...Nature Communications 13 (1), 4622, 2022912022
3-) LBA72 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trialMF Mosele, A Lusque, VC Dieras, E Deluche, A Ducoulombier, B Pistilli, ...Annals of Oncology 33, S1440, 2022572022
4-) Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancerF Facchinetti, A Hollebecque, F Braye, D Vasseur, Y Pradat, R Bahleda, ...Cancer discovery 13 (9), 1998-2011, 2023322023
5-) CustOmics: A versatile deep-learning based strategy for multi-omics integrationH Benkirane, Y Pradat, S Michiels, PH CournèdePLOS Computational Biology 19 (3), e1010921, 2023292023